Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers

Round 1

Reviewer 1 Report

The topic is interesting and the writing style is good. However, some points have to be corrected prior to publication.

1)      The abstract is brief and needs to be expanded.

2)      The manuscript will absorb more readers if the authors provide an appropriate graphical abstract ( Perhaps they can modify Fig 5 and use it as the graphical abstract.

3)      The sub-title of 2- Epigenetics and epigenetic modification is irrelevant to the text. It should be corrected to something like “correlation between histone modifications and tumorigenesis” Because in the text histone modification and tumorigenesis have be discussed.

4)      Figs 1,2,3 have to be described further in the text. Authors can use this paper as a reference for describing figure 2. https://academic.oup.com/nar/article/39/5/1680/2409413?login=false 

5)      It is good if the authors provide a Venn diagram  to show the comprehensive roles of LSD1 in both pathological and healthy conditions. 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The review article provides a comprehensive summary of immunomodulatory effects of epigenetic modifications mediated by LSD1. The scope of LSD1 inhibition has been thoroughly researched and presented in the article. A good amount of information has been presented on the existing preclinical studies and clinical trials. A thorough description on existing clinical trials relating LSD1 with breast cancer has also been provided as much as possible. It is a well written article and my major comment would only be to make a smoother transition from epigenetic modifiers into ICB therapies leading to LSD1 inhibition benefits. Here is a description of points that could be improved in my opinion:

 

·      Line 57: miRNA, although being a major type of non-coding RNA (ncRNA) that takes part in epigenetic modifications, there are other ncRNAs that are currently being researched and have proven their role in epigenetic modifications. Please make necessary changes in the text and in the corresponding Figure 1.

·      Figures 1 and 2 need better description in lines 77 and 79.

·      The article makes a sudden transition into current challenges faced with ICB therapies right after discussing epigenetic modification types. It would help the readers process the information better with a proper introduction to ICB therapies and if a smoother transition is established between sections 2 and 3.

·      The readers might benefit from more information about how conserved the structure of LSD1 is in different organisms.

·      Readers might benefit with a better description of Figure 4. It would be helpful to mark the X-ray diffraction structure with the different domains of the protein.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 3 Report

This is a really well edited and recapulative review of LSD1 function in breast cancer.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The authors provided my corrections, but regarding comment #4, when it used the results in lines 94-99, I would suggest citing it in Ref. 

Author Response

Please see the attachment

Author Response File: Author Response.pdf